Here, we measured SARS-CoV-2-specific antibodies (including neutralizing antibodies), SARS-CoV-2-specific CD4+ T cells, and SARS-CoV-2-specific CD8+ T cells in all individuals in a new cohort, with an emphasis on including acute cases across a range of COVID-19 disease severities. This evidence concerns the gene CD4 and COVID-19.